Sven Mahner

Summary

Country: Germany

Publications

  1. pmc TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    BMC Cancer 10:139. 2010
  2. doi request reprint Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
    Sven Mahner
    Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group AGO and University Medical Center Hamburg Eppendorf, Germany Electronic address
    Eur J Cancer 51:352-8. 2015
  3. doi request reprint Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials
    S Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Eur J Cancer 49:142-9. 2013
  4. pmc A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Cancer Res Clin Oncol 138:1413-9. 2012
  5. ncbi request reprint Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction
    Sven Mahner
    Department of Gynecology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany
    Anticancer Res 29:2817-21. 2009
  6. doi request reprint Serum carbonic anhydrase IX during first-line therapy of ovarian cancer
    Linn Woelber
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Gynecol Oncol 117:183-8. 2010
  7. doi request reprint Adjuvant therapy in node-positive vulvar cancer
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Germany
    Expert Rev Anticancer Ther 13:839-44. 2013
  8. doi request reprint Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer
    Lilli Kock
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Int J Gynecol Cancer 21:141-8. 2011
  9. doi request reprint Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva
    Linn Woelber
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Ann Surg Oncol 18:3811-8. 2011
  10. doi request reprint Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer
    Sabrina Mathey
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Oncology 85:69-77. 2013

Collaborators

Detail Information

Publications47

  1. pmc TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    BMC Cancer 10:139. 2010
    ..The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear...
  2. doi request reprint Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
    Sven Mahner
    Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group AGO and University Medical Center Hamburg Eppendorf, Germany Electronic address
    Eur J Cancer 51:352-8. 2015
    ..To perform a subset analysis of patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial...
  3. doi request reprint Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials
    S Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Eur J Cancer 49:142-9. 2013
    ..The impact of the time interval between surgery and initiation of chemotherapy for clinical outcome has not been clarified yet...
  4. pmc A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Cancer Res Clin Oncol 138:1413-9. 2012
    ....
  5. ncbi request reprint Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction
    Sven Mahner
    Department of Gynecology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany
    Anticancer Res 29:2817-21. 2009
    ..Routine measurement of the tumor marker CA-125 is often used in the follow-up management. However, the role of preoperative CA-125 as a prognostic factor before secondary cytoreduction of relapsed ovarian cancer has not been determined...
  6. doi request reprint Serum carbonic anhydrase IX during first-line therapy of ovarian cancer
    Linn Woelber
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Gynecol Oncol 117:183-8. 2010
    ..It is overexpressed in a variety of tumors including ovarian cancer. To evaluate the potential prognostic and predictive role of serum CAIX for therapy response in ovarian cancer, we analyzed longitudinal serum samples...
  7. doi request reprint Adjuvant therapy in node-positive vulvar cancer
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Germany
    Expert Rev Anticancer Ther 13:839-44. 2013
    ..This review discusses existing evidence focusing on different therapeutic approaches and their potential indication in vulvar cancer. Based on the available data the need for future trials is being elaborated. ..
  8. doi request reprint Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer
    Lilli Kock
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Int J Gynecol Cancer 21:141-8. 2011
    ..We therefore determined CAIX serum concentration and its prognostic relevance in correlation to intratumoral CAIX expression in patients with primary vulvar cancer...
  9. doi request reprint Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva
    Linn Woelber
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Ann Surg Oncol 18:3811-8. 2011
    ..A tumor-free resection margin of at least 8 mm is considered state of the art in vulvar cancer. This standard is based on small and heterogeneous patient cohorts, and its implementation can result in mutilation...
  10. doi request reprint Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer
    Sabrina Mathey
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Oncology 85:69-77. 2013
    ..The interaction of platelet-derived growth factor receptor-beta (PDGFR-β) with vascular endothelial growth factor (VEGF) in the process of angiogenesis may represent an essential feature in the progression of the disease...
  11. doi request reprint Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome
    Isabell D Witzel
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    J Cancer Res Clin Oncol 136:1709-18. 2010
    ..To investigate the correlation between RNA and protein levels, we assessed HER2, uPA and PAI-1 in patients with breast cancer. In addition, we evaluated the influence of these factors on patient outcome...
  12. pmc Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients
    Maike Ihnen
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    BMC Cancer 12:140. 2012
    ..In some cancers ALCAM has a prognostic value or is predictive for the benefit of therapeutic interventions. To date there are no data on the role of ALCAM in cervical cancer available...
  13. doi request reprint Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment
    Linn Woelber
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Int J Gynecol Cancer 22:503-8. 2012
    ..However, information regarding the impact of the number of positive nodes in vulvar cancer is inconsistent, and so are recommendations when to apply adjuvant radiotherapy...
  14. doi request reprint Prognostic factors for complete debulking in first- and second-line ovarian cancer
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Ludwig Erhard Strasse 100, Wiesbaden, Germany
    Int J Gynecol Cancer 19:S14-7. 2009
    ..Surgery is a mainstay of therapy in ovarian cancer. Are there any actual changes in the definitions and goals of surgery?..
  15. doi request reprint Secondary sentinel node biopsy after previous excision of the primary tumor in squamous cell carcinoma of the vulva
    Linn Woelber
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Ann Surg Oncol 20:1701-6. 2013
    ..It has been proven to be a safe alternative in early-stage disease. Feasibility and safety of the procedure after previous vulvar surgery remain unclear...
  16. pmc Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer
    Linn Woelber
    Department of Gynecology and Gynecologic Oncology, University Medical Centre Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    BMC Cancer 11:12. 2011
    ..The protein is overexpressed in a variety of tumors and potentially associated with negative outcome. This study was designed to investigate the prognostic role of CAIX in serum and tumor tissue of patients with primary cervical cancer...
  17. doi request reprint Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig Erhard Strasse 100, D 65199 Wiesbaden, Germany
    Expert Rev Anticancer Ther 10:81-8. 2010
    ..Actual treatment options and strategies in recurrent ovarian cancer will also be discussed. Furthermore, this review focuses on new drugs in the treatment of primary and recurrent ovarian cancer...
  18. doi request reprint Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer
    Dina Mury
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
    J Cancer Res Clin Oncol 137:1131-7. 2011
    ..To stratify patients for optimal therapy, prognostic and predictive factors are needed. We examined the role of pre- and postoperative CA-125 in this context...
  19. pmc Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
    Fabian Trillsch
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, Hamburg, 20246, Germany
    J Ovarian Res 6:42. 2013
    ..Approximately one third of women diagnosed with ovarian cancer is 70 years or older. Information on the treatment reality of these elderly patients is limited...
  20. doi request reprint Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study
    Linn Woelber
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany Electronic address
    Eur J Cancer 69:180-188. 2016
    ..Available evidence is based on heterogeneous cohorts. This study was designed to clarify the relevance of the resection margin for loco-regional control in vulvar cancer...
  21. doi request reprint Clinical management of epithelial ovarian cancer during pregnancy
    Donata Grimm
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Eur J Cancer 50:963-71. 2014
    ....
  22. doi request reprint The prognostic significance of Jun transcription factors in ovarian cancer
    Kerstin Eckhoff
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistr 52, Bldg N27, 20246, Hamburg, Germany
    J Cancer Res Clin Oncol 139:1673-80. 2013
    ..However, little is known about the prognostic significance of Jun proteins in patients with invasive epithelial ovarian carcinoma...
  23. doi request reprint Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD
    Radoslav Chekerov
    Department of Gynecology, European Competence Centre for Ovarian Cancer, Charite University Hospital, Campus Virchow, Berlin, Germany
    Int J Gynecol Cancer 23:268-75. 2013
    ..Here we present the main pathologic, surgical, and chemotherapy characteristics of the OVCAD patient cohort...
  24. pmc Management of patients with vulvar cancer: a perspective review according to tumour stage
    Linn Woelber
    Department of Gynaecology and Gynaecologic Oncology, University Medical Centre Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Ther Adv Med Oncol 5:183-92. 2013
    ..This review therefore puts different recommendations of clinical management in context and highlights the need for future trials...
  25. ncbi request reprint Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer
    Linn Woelber
    Department of Gynaecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Anticancer Res 29:545-52. 2009
    ..The aim of this study was to determine prognostic variables for recurrence and survival and to identify patterns of recurrence in patients with vulvar cancer...
  26. doi request reprint Clinical management of primary vulvar cancer
    Linn Woelber
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Eur J Cancer 47:2315-21. 2011
    ..This article discusses the current literature to elaborate recommendations for the management of primary vulvar cancer in clinical routine...
  27. doi request reprint Patterns of distant metastases in vulvar cancer
    Katharina Prieske
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Gynecol Oncol 142:427-34. 2016
    ..Metastatic vulvar cancer is a rare disease. Information on metastatic patterns and corresponding prognosis or therapeutic approaches is scarce. We therefore analyzed pattern and course of metastatic disease in a large single center cohort...
  28. pmc Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT)
    Fabian Trillsch
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    J Ovarian Res 6:48. 2013
    ..As these patients have an excellent overall prognosis, perioperative morbidity is the critical point for decision making when the treatment strategy is developed and the primary surgical approach is defined...
  29. doi request reprint The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node
    Linn Woelber
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Ann Surg Oncol 23:2508-14. 2016
    ..The risk of contralateral non-SLN metastasis is unclear...
  30. doi request reprint Systemic treatment of vulvar cancer
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Martinistrase 52, Hamburg 20246, Germany
    Expert Rev Anticancer Ther 15:629-37. 2015
    ....
  31. doi request reprint Sexual Activity and Function in Patients With Gynecological Malignancies After Completed Treatment
    Donata Grimm
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg Department of Gynecology and Gynecologic Oncology, University Hospital Freiburg, Freiburg Department of Medical Biometry and Epidemiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Int J Gynecol Cancer 25:1134-41. 2015
    ..The aim of this study was to analyze the sexual outcome and overall QoL of women after treatment for primary GC compared with a healthy control group (CG)...
  32. doi request reprint Sexual activity and function after surgical treatment in patients with (pre)invasive vulvar lesions
    Donata Grimm
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Martinistrase 52, 20246, Hamburg, Germany
    Support Care Cancer 24:419-28. 2016
    ..Data on sexuality after treatment are scarce...
  33. doi request reprint Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases
    Matthias Choschzick
    Institute of Pathology, University Medical Centre Hamburg Eppendorf, Hamburg, Germany
    Virchows Arch 456:483-90. 2010
    ..Our data support the potential therapeutic benefit of newly developed targeting antibodies in advanced vulvar cancer...
  34. doi request reprint Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients
    Jalid Sehouli
    Department of Gynecology, University of Berlin, Charite, Campus Virchow, Berlin, Germany Electronic address
    Eur J Cancer 51:825-32. 2015
    ..Some patients and physicians believe that alopecia could be a surrogate marker for response to chemotherapy and impact on prognosis. However, this was never been tested in a sufficiently large cohort of ovarian cancer patients...
  35. doi request reprint Assessment of cervical intraepithelial neoplasia (CIN) with colposcopic biopsy and efficacy of loop electrosurgical excision procedure (LEEP)
    Nina Duesing
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
    Arch Gynecol Obstet 286:1549-54. 2012
    ..The present study analyses the accuracy of preoperative assessment of CIN with cytology plus colposcopic biopsy and assesses the efficacy of LEEP for the treatment of CIN...
  36. pmc Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany SM, LFG, LW Department of Obstetrics and Gynecology, University Hospital Munich Maistrasse, Munich, Germany JJ Department of Obstetrics and Gynecology, University Medical Center Kiel, Kiel, Germany FH KKS Philipps University Marburg, Marburg, Germany PN Department of Gynecology and Gynecologic Oncology Kliniken Essen Mitte, Essen, Germany PH, AdB Department of Obstetrics and Gynecology, University of Ulm Medical Center, Ulm, Germany NdG Department of Gynecology and Gynecologic Oncology, University Hospital Freiburg, Freiburg, Germany AHas Department of Gynecology, Charité University Medicine Berlin Campus Virchow, Berlin, Germany JS Department of Obstetrics and Gynecology, University Hospital Magdeburg, Magdeburg, Germany AHab Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany PH Department of Obstetrics and Gynecology, Grosshadern University Hospital, Munich, Germany SF Department of Gynecology, University Hospital Halle, Halle, Germany HGS Department of Gynecology and Gynecologic Oncology, Philipps University Marburg
    J Natl Cancer Inst 107:. 2015
    ..Indication criteria for adjuvant radiotherapy are controversial. This study was designed to further understand the role of adjuvant therapy in node-positive disease...
  37. pmc Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function
    Charlotte VON Bülow
    Department of Gynecology, University Medical Center Hamburg Eppendorf, D 20246 Hamburg, Germany
    Mol Clin Oncol 3:1067-1072. 2015
    ..However, the recurrence-free and overall survival analyses did not reveal any prognostic or predictive significance. In conclusion, in contrast to other tumor types, CDH11 does not play an important role in ovarian cancer progression...
  38. ncbi request reprint Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7)
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen Department of Gynecology, Charité Medical University of Berlin, Berlin Coordinating Center for Clinical Trials, University Marburg Department of Gynecology, Gynecologic Endocrinology and Oncology, Philipps University Marburg, Marburg Department of Obstetrics and Gynecology, Johann Wolfgang Goethe University, Frankfurt Department of Obstetrics and Gynecology, University Hospital Schleswig Holstein, Campus Lubeck, Lübeck Department of Obstetrics and Gynecology, University of Duisburg Essen, Essen Department of Gynecologic Oncology and Gynecology, Gynaekologicum Bremen, Bremen Department of Obstetrics and Gynecology, Ludwig Maximilians University Munich, München Department of Obstetrics and Gynecology, Oberschwabenklinik Hospital St Elisabeth Ravensburg, Ravensburg Department of Obstetrics and Gynecology, University Hospital Ulm, Ulm Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg Department of Obstetrics and Gynecology, Carl Gustav Carus Technische University Dresden, Dresden Gynecology Hannover, Hannover Department of Obstetrics and Gynecology, Ev Hospital Düsseldorf, Dusseldorf Department of Obstetrics and Gynecology, University of Tubingen, Tübingen and Department of Obstetrics and Gynecology, Karolinska sjukhuset
    Int J Gynecol Cancer 26:1636-1641. 2016
    ..Platinum and anthracyclines were reported as active agents in gynecologic sarcoma and carcinosarcoma. So far, data regarding the combination of carboplatin and pegylated liposomal doxorubicin for this patient population are missing...
  39. pmc Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
    Xiaodan Meng
    Department of Tumor Biology, University Medical Center Hamburg Eppendorf, Hamburg 20246, Germany
    Br J Cancer 113:1358-66. 2015
    ..Owing to late diagnosis in advanced disease stages, prognosis of patients with epithelial ovarian cancer (EOC) is poor. The quantification of deregulated levels of microRNAs could facilitate earlier diagnosis and improve prognosis of EOC...
  40. doi request reprint Role of cytoreductive surgery in recurrent ovarian cancer
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig Erhard Str 100, D 65199 Wiesbaden, Germany
    Expert Rev Anticancer Ther 9:917-22. 2009
    ..The surgical end point in recurrent ovarian cancer should be complete resection. Predictive factors could help identify patients in whom complete resection is possible...
  41. doi request reprint Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Wiesbaden, Germany
    Int J Gynecol Cancer 21:289-95. 2011
    ..The DESKTOP II trial was planned to verify this hypothesis prospectively in a multicenter setting...
  42. doi request reprint The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study
    Mani Nassir
    Department of Gynecology, Tumor Bank Ovarian Cancer TOC, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany
    Tumour Biol 37:3009-16. 2016
    ..For the estimated median overall survival (OS), our analysis revealed similar results. HE4 in combination with CA125 performed better than CA125 and HE4 alone in predicting recurrence within 12 months after first-line chemotherapy. ..
  43. pmc A systematic model specification procedure for an illness-death model without recovery
    Christine Eulenburg
    Department of Medical Biometry and Epidemiology University Medical Center Hamburg Eppendorf, Hamburg, Germany
    PLoS ONE 10:e0123489. 2015
    ..This stepwise procedure yields parsimonious but targeted multi-state models with well interpretable coefficients and optimized predictive ability, even for smaller data sets. ..
  44. doi request reprint Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial
    Antonio González-Martín
    and Medical Oncology Department, MD Anderson Cancer Center, Madrid, Spain GINECO and Medical Oncology Department, Institut Gustave Roussy, Villejuif, France AGO and Department of Gynaecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany Coordinating Center for Clinical Trials, Philipps University of Marburg, Marburg, Germany MaNGO and Division of Medical Gynecologic Oncology, European Institute of Oncology and University of Milan Bicocca, Milan, Italy DGOG and Department of MedicalOncology, Radboud University Medical Center, Nijmegen, The Netherlands GEICO and Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain GINECO and Tenon Hospital AP HP and Alliance Pour la Recherche en Cancérologie, France AGO and Department of Gynecology and GynecologicOncology, Kliniken Essen Mitte, Evang Huyssens Stiftung Knappschaft GmbH, Essen, Germany MaNGO and Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy GEICO and Medical Oncology Department, Parc Taulí Sabadell Hospital Universitari, Sabadell, Spain GINECO and Medical Oncology Department, Integrated Center for Oncology Nantes Angers, Nantes, France AGO and National Centre for Tumour Diseases, Division of Gynaecologic Oncology, University Hospital Heidelberg, Department of Pediatrics
    Int J Gynecol Cancer 26:898-905. 2016
    ..The 2-part PENELOPE trial (NCT01684878) is prospectively investigating pertuzumab plus chemotherapy in this population...
  45. doi request reprint In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines
    Tarik Ghadban
    Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg Eppendorf, D 20246 Hamburg, Germany
    Int J Mol Med 38:1296-302. 2016
    ..HSP70 was upregulated, but HSP27 expression was not affected. Our data indicate that 17-AEPGA and 17-DMAG are highly active in breast cancer cell lines and may help to overcome the delivery issues associated with the use of 17-AAG. ..
  46. pmc Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
    Hannah Woopen
    Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charite University Medicine of Berlin, Berlin, Germany
    J Gynecol Oncol 25:221-8. 2014
    ..Aim of this study was to study EpCAM as a potential prognostic marker in epithelial ovarian cancer (EOC)...
  47. ncbi request reprint Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines
    Sibyll Hein
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Oncol Rep 22:177-83. 2009
    ..No correlation with the proliferative and invasive potential of ovarian cancer cell lines could be found...